Sponsor Check › Person
Related person on Form D filings · address states as listed: MA, NC, CA · listed May 14, 2009 → Mar 1, 2023
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:18 AM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 24, 2026, 2:18 AM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
No SEC search has run yet for this person.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:18 AM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
4 of 62 offerings report sales commissions totalling $8,596,874; 2 report finder's fees totalling $2,665,000; 2 report proceeds to related persons totalling $4,355,000. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Mar 1, 2023 D File 021-474629 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 21, 2022 D File 021-449708 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 10, 2022 D File 021-433075 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director, manager or promoter will receive any payments from the proceeds of this offering. | None listed on this filing |
| EDGAR ↗ | Feb 4, 2022 D File 021-432397 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 29, 2021 D/A File 021-392937 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 17, 2020 D File 021-383597 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 6, 2020 D File 021-379891 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 2, 2020 D File 021-379484 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 26, 2020 D File 021-374148 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 24, 2020 D File 021-369623 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 21, 2020 D File 021-365465 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 2, 2020 D File 021-357026 | $4,200,000 | $0 | $0 | Cantor Fitzgerald LP BrokerCheck CRD 134 ↗ Needham & Company BrokerCheck CRD 16360 ↗ Canaccord Genuity LLC BrokerCheck CRD 1020 ↗ Janney Montgomery Scott LLC BrokerCheck CRD 463 ↗ |
| EDGAR ↗ | Sep 4, 2019 D File 021-347952 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 24, 2019 D File 021-344976 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 17, 2019 D File 021-342127 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 1, 2018 D File 021-322473 | $0 | $0 | $2,600,000 (est.) | None listed on this filing |
| EDGAR ↗ | Sep 25, 2018 D File 021-322125 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 17, 2018 D File 021-317048 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director, manager or promoter will receive any payments from the proceeds of this offering. | None listed on this filing |
| EDGAR ↗ | Jun 20, 2018 D File 021-314940 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 9, 2018 D/A File 021-303459 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 8, 2018 D File 021-302683 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 13, 2017 D File 021-300578 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 1, 2017 D File 021-297859 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 27, 2017 D/A File 021-271393 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 11, 2017 D File 021-290444 | $2,640,000 (est.) | $0 | $0 | Stifel, Nicolaus & Company Incorporated BrokerCheck CRD 793 ↗ |
| EDGAR ↗ | May 12, 2017 D File 021-286616 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 14, 2016 D File 021-276281 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 8, 2016 D File 021-275847 | $1,664,999 | $0 | $0 | LEERINK PARTNERS LLC BrokerCheck CRD 39011 ↗ |
| EDGAR ↗ | Nov 9, 2016 D/A File 021-237785 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 19, 2016 D File 021-269268 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 12, 2016 D File 021-266843 | $0 | $0 | $0 | Denning & Company LLC BrokerCheck CRD 115971 ↗ |
| EDGAR ↗ | May 11, 2016 D File 021-262957 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 4, 2016 D File 021-254433 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 10, 2015 D File 021-247362 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 21, 2015 D File 021-246215 | $0 | $0 | $0 Other than the payment of salaries and other compensation and benefits, no officer, director, manager or promoter will receive any payments from the proceeds of this offering. | None listed on this filing |
| EDGAR ↗ | May 18, 2015 D File 021-240107 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 23, 2015 D File 021-238498 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 2, 2015 D File 021-237156 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 12, 2015 D/A File 021-219742 | $0 | $2,650,000 | $0 | Denning & Company LLC BrokerCheck CRD 115971 ↗ |
| EDGAR ↗ | Aug 28, 2014 D File 021-223752 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 6, 2014 D File 021-222370 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 15, 2014 D File 021-221143 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 9, 2014 D File 021-215195 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 13, 2013 D File 021-201262 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 10, 2013 D File 021-199298 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 8, 2013 D File 021-191591 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 21, 2012 D File 021-183005 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 17, 2012 D File 021-173676 | $0 | $0 | $1,755,000 (est.) This is the sum of budgeted salaries for the applicable executive officers and one consultant/member of the Board for the next 12 months. | None listed on this filing |
| EDGAR ↗ | Nov 22, 2011 D File 021-169119 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 17, 2011 D File 021-168905 | $0 | $0 | $0 None other than salaries and bonuses in the ordinary course of business. | None listed on this filing |
| EDGAR ↗ | Nov 17, 2011 D File 021-168906 | $0 | $0 | $0 None other than salaries and bonuses in the ordinary course of business. | None listed on this filing |
| EDGAR ↗ | Oct 13, 2011 D File 021-167172 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 20, 2011 D/A File 021-117892 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 20, 2011 D File 021-158650 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 13, 2010 D File 021-148941 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 6, 2010 D/A File 021-117636 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 29, 2010 D File 021-144139 | $0 | $0 | $0 Not including salaries and bonuses paid to executive officers in the ordinary course of business. | None listed on this filing |
| EDGAR ↗ | Jun 10, 2010 D File 021-143299 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 6, 2010 D File 021-125893 | $0 | $0 | $0 None other than salaries and bonuses in the ordinary course of business. | None listed on this filing |
| EDGAR ↗ | Nov 2, 2009 D File 021-43237 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 15, 2009 D File 021-71452 | $91,875 (est.) | $15,000 | $0 | Musket Research Associates, Inc. BrokerCheck CRD 30599 ↗ via David B. Musket (CRD 1321808 ↗) |
| EDGAR ↗ | Jun 18, 2009 D File 021-108750 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | Morphic Holding, Inc. | Director | Mar 1, 2023 | D | $100,000,000 similar: $2,000,000–$19,999,994 | $99,999,755 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Camp4 Therapeutics Corp | Director | Jun 21, 2022 | D | Indefinite similar: $2,000,000–$19,999,994 | $100,494,015 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AgBiome, LLC | Director Member of Board of Managers | Feb 10, 2022 | D | $117,179,074 similar: $675,000–$10,000,000 | $117,179,074 | 22 similar: 1–12 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Dewpoint Therapeutics, Inc. | Director | Feb 4, 2022 | D | $149,999,989 similar: $2,000,000–$19,999,994 | $149,999,989 | 18 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Camp4 Therapeutics Corp | Director | Oct 29, 2021 | D/A | Indefinite similar: $2,000,000–$19,999,994 | $44,999,960 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Camp4 Therapeutics Corp | Director | Mar 19, 2021 | D | Indefinite similar: $2,000,000–$19,999,994 | $15,000,000 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Syros Pharmaceuticals, Inc. | Director | Dec 17, 2020 | D | $121,609,375 similar: $2,000,000–$19,999,994 | $90,490,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Primmune Therapeutics, Inc. | Director | Nov 6, 2020 | D | $24,000,008 similar: $1,694,259–$16,000,000 | $13,000,009 | 12 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Dewpoint Therapeutics, Inc. | Executive Officer, Director | Nov 2, 2020 | D | $77,097,477 similar: $2,000,000–$19,999,994 | $77,097,477 | 25 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Freenome Holdings, Inc. | Director | Aug 26, 2020 | D | $269,999,879 similar: $1,100,015–$10,001,163 | $269,999,879 | 55 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Polaris Healthcare Technology Opportunities Fund, L.P. group: Polaris | Executive Officer Managing Member of the General Partner | Jun 24, 2020 | D | $100,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Apr 21, 2020 | D | $50,000,024 similar: $2,000,000–$19,999,994 | $50,000,024 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Cartesian Therapeutics, Inc. | Director | Jan 2, 2020 | D | $70,000,000 similar: $2,000,000–$19,999,994 | $70,000,000 | 26 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Cartesian Therapeutics, Inc. | Director | Sep 4, 2019 | D | $5,752,495 similar: $2,000,000–$19,999,994 | $5,752,495 | 10 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Freenome Holdings, Inc. | Director | Jul 24, 2019 | D | $159,999,918 similar: $500,000–$7,000,000 | $159,999,918 | 47 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Polaris Partners IX, L.P. group: Polaris | Executive Officer | Jun 17, 2019 | D | $400,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Morphic Holding, Inc. | Director | Oct 1, 2018 | D | $79,999,990 similar: $2,000,000–$19,999,994 | $79,999,990 | 13 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Camp4 Therapeutics Corp | Director | Sep 25, 2018 | D | $34,080,628 similar: $2,000,000–$19,999,994 | $34,080,628 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AgBiome, LLC | Director Manager | Jul 17, 2018 | D | $65,000,000 similar: $675,000–$10,000,000 | $65,000,000 | 17 similar: 1–12 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Metacrine, Inc. | Director | Jun 20, 2018 | D | $65,000,000 similar: $1,694,259–$16,000,000 | $65,000,000 | 26 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Syros Pharmaceuticals, Inc. | Director | Feb 9, 2018 | D/A | $11,380,018 similar: $2,000,000–$19,999,994 | $11,380,018 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Syros Pharmaceuticals, Inc. | Director | Jan 17, 2018 | D | $9,999,995 similar: $2,000,000–$19,999,994 | $9,999,995 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Scholar Rock Holding Corp group: Scholar Rock | Director | Jan 8, 2018 | D | $47,000,000 similar: $2,000,000–$19,999,994 | $46,999,998 | 19 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Metacrine, Inc. | Director | Dec 13, 2017 | D | $22,000,000 similar: $1,694,259–$16,000,000 | $22,000,000 | 7 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CubicPV Inc. | Director | Nov 1, 2017 | D | $9,023,314 similar: $1,100,015–$10,001,163 | $8,183,483 | 10 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Sofregen Medical Inc. | Director | Sep 27, 2017 | D/A | $9,700,005 similar: $2,000,000–$19,999,994 | $9,700,005 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Cartesian Therapeutics, Inc. | Director | Jul 11, 2017 | D | $50,000,000 similar: $2,000,000–$19,999,994 | $50,000,000 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Polaris Entrepreneurs' Fund VIII, L.P. group: Polaris | Executive Officer | May 12, 2017 | D | $14,470,000 similar: $155,000–$5,250,000 | $14,470,000 | 34 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Cartesian Therapeutics, Inc. | Director | Dec 14, 2016 | D | $4,999,984 similar: $2,000,000–$19,999,994 | $4,999,984 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Dec 8, 2016 | D | $56,749,988 similar: $2,000,000–$19,999,994 | $56,749,988 | 21 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Metacrine, Inc. | Director | Nov 9, 2016 | D/A | $37,766,644 similar: $1,694,259–$16,000,000 | $37,766,644 | 20 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Sofregen Medical Inc. | Director | Sep 27, 2016 | D | $6,200,005 similar: $2,000,000–$19,999,994 | $6,200,005 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Aug 19, 2016 | D | $10,290,000 similar: $2,000,000–$19,999,994 | $10,290,000 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Polaris Partners VIII, L.P. group: Polaris | Executive Officer | Jul 12, 2016 | D | $400,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | CubicPV Inc. | Director | May 11, 2016 | D | $30,000,000 similar: $1,100,015–$10,001,163 | $10,000,000 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Scholar Rock LLC group: Scholar Rock | Director | Jan 4, 2016 | D | $40,000,000 similar: $2,000,000–$19,999,994 | $36,296,355 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Metacrine, Inc. | Director | Oct 6, 2015 | D/A | $36,449,979 similar: $1,694,259–$16,000,000 | $12,149,995 | 18 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Cartesian Therapeutics, Inc. | Director | Sep 10, 2015 | D | $40,637,943 similar: $2,000,000–$19,999,994 | $37,400,000 | 19 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | AgBiome, LLC | Director Manager | Aug 21, 2015 | D | $34,500,387 similar: $675,000–$10,000,000 | $34,500,387 | 10 similar: 1–12 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | May 18, 2015 | D | $8,000,000 similar: $2,000,000–$19,999,994 | $8,000,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Cartesian Therapeutics, Inc. | Director | Apr 23, 2015 | D | $7,500,000 similar: $2,000,000–$19,999,994 | $5,942,306 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | aTYR PHARMA INC | Director Non-Management Director | Apr 2, 2015 | D | $76,278,755 similar: $2,000,000–$19,999,994 | $76,278,755 | 42 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Polaris Partners VII, L.P. group: Polaris | Executive Officer | Feb 12, 2015 | D/A | $435,555,556 similar: $155,000–$5,250,000 | $435,555,556 | 43 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Cartesian Therapeutics, Inc. | Director | Aug 28, 2014 | D | $4,450,000 similar: $2,000,000–$19,999,994 | $4,450,000 | 11 similar: 2–16 | $100,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Polaris Entrepreneurs' Fund VII, L.P. group: Polaris | Director | Aug 6, 2014 | D | $30,000,000 similar: $155,000–$5,250,000 | $26,000,000 | 33 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Cartesian Therapeutics, Inc. | Director | Jul 15, 2014 | D | $6,000,000 similar: $2,000,000–$19,999,994 | $6,000,000 | 2 similar: 2–16 | $3,000,000 similar: $10,000–$50,000 |
| EDGAR ↗ | Polaris Partners VII, L.P. group: Polaris | Executive Officer | Jun 25, 2014 | D/A | $400,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Polaris Partners VII, L.P. group: Polaris | Executive Officer | Jun 24, 2014 | D | $400,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Cartesian Therapeutics, Inc. | Director | Apr 9, 2014 | D | $9,999,994 similar: $2,000,000–$19,999,994 | $5,292,702 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Aug 13, 2013 | D | $20,000,000 | $20,000,000 | 3 | No minimum reported |
| EDGAR ↗ | Sun Catalytix Corp | Director | Jul 10, 2013 | D | $12,000,002 | $4,000,001 | 5 | No minimum reported |
| EDGAR ↗ | BIND Biosciences, Inc | Director | Feb 8, 2013 | D | $20,250,000 | $8,697,684 | 20 | No minimum reported |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Aug 21, 2012 | D | Indefinite | $9,244,679 | 17 | No minimum reported |
| EDGAR ↗ | Receptos, Inc. | Director | Feb 17, 2012 | D | $50,000,011 | $10,806,610 | 11 | No minimum reported |
| EDGAR ↗ | BIND Biosciences, Inc | Director | Nov 22, 2011 | D | $47,297,179 | $25,547,174 | 21 | No minimum reported |
| EDGAR ↗ | Cartesian Therapeutics, Inc. | Director | Nov 17, 2011 | D | $26,000,000 | $3,500,000 | 1 | No minimum reported |
| EDGAR ↗ | Cartesian Therapeutics, Inc. | Director | Nov 17, 2011 | D | $22,000,000 | $22,000,000 | 16 | No minimum reported |
| EDGAR ↗ | BIND Biosciences, Inc | Director | Oct 13, 2011 | D | $4,750,000 | $4,750,000 | 5 | No minimum reported |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Apr 20, 2011 | D | $1,000,000 | $1,000,000 | 1 | No minimum reported |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Apr 20, 2011 | D/A | $35,988,360 | $35,988,360 | 18 | No minimum reported |
| EDGAR ↗ | Sun Catalytix Corp | Executive Officer | Oct 13, 2010 | D | $9,584,374 | $9,584,374 | 8 | No minimum reported |
| EDGAR ↗ | AVILA THERAPEUTICS INC | Director | Jul 6, 2010 | D/A | $30,000,000 | $22,500,000 | 9 | No minimum reported |
| EDGAR ↗ | BIND Biosciences, Inc | Director | Jun 29, 2010 | D | $12,420,952 | $12,420,952 | 18 | No minimum reported |
| EDGAR ↗ | Polaris Venture Partners VI, L.P. group: Polaris | Director | Jun 10, 2010 | D | $400,000,000 | $233,750,000 | 34 | No minimum reported |
| EDGAR ↗ | Cartesian Therapeutics, Inc. | Director | Apr 6, 2010 | D | $15,000,006 | $15,000,006 | 14 | No minimum reported |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Dec 24, 2009 | D/A | $32,488,360 | $32,488,360 | 16 | No minimum reported |
| EDGAR ↗ | FATE THERAPEUTICS INC | Director | Nov 23, 2009 | D | $30,488,360 | $30,488,360 | 16 | No minimum reported |
| EDGAR ↗ | ATHENIX CORP | Director | Nov 2, 2009 | D | $5,000,000 | $0 | 0 | No minimum reported |
| EDGAR ↗ | Pervasis Therapeutics Inc | Director | Sep 15, 2009 | D | $17,384,210 | $10,003,426 | 18 | No minimum reported |
| EDGAR ↗ | AVILA THERAPEUTICS INC | Director | Jul 31, 2009 | D | $30,000,000 | $17,500,000 | 9 | $9,531 |
| EDGAR ↗ | LIVING PROOF INC | Executive Officer, Director | Jun 18, 2009 | D | $9,000,000 | $9,000,000 | 4 | No minimum reported |
| EDGAR ↗ | AVILA THERAPEUTICS INC | Director | May 14, 2009 | D | $20,000,000 | $5,000,000 | 8 | $7,206 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (6 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Separate person records under the same name, not combined with this page. Each line says whether it is listed on an issuer this record is also listed on (a second identifier); where it is not, it could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Amir Nashat. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Amir Nashat appears on a new Form D, or when a court case or SEC action is matched to them. See plans →